September 5, 2012

Benchmark Holdings acquires UK-based vaccine manufacturing facility

Benchmark Holdings has announced the acquisition of a Novartis Animal Health vaccine manufacturing facility in Braintree, UK.

The acquisition is effective immediately and ensures continuity of production and jobs at the facility.

The Braintree plant has been producing licensed veterinary vaccines for Novartis and other major pharmaceutical companies for over 25 years. Under Benchmark, the plant's role as a toll manufacturer will be expanded. Following a major investment in production and R&D capability at the plant new specialist small- to medium-scale products will be manufactured for developing world markets.

Benchmark Holdings is delighted with the addition of the Braintree plant to the Benchmark family, an excellent team in a first class facility. It also provides a great fit with the existing businesses.

The business will maintain Benchmark's core ethical philosophy based on the 3Es of ethical, environmental and economic business practices.

Terms of the acquisition are confidential.